Unlocking Cures for Pediatric Cancer With Artificial Intelligence
Record date: 2025-10-07
Executive Order 14355 of September 30, 2025 Unlocking Cures for Pediatric Cancer With Artificial Intelligence By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered: Section 1 . Purpose and Policy. My Administration is committed to driving innovation to prevent and treat childhood diseases, including through the use of artificial intelligence (AI). Pediatric cancer remains the leading cause of disease-related death for children in the United States aged 1-19 years, and its incidence has increased by
What this record contains
- Federal Register document
- 2025-19495
- Publication date
- 2025-10-07
- Citation
- 90 FR 48153
- Issuing office
- Executive Office of the President
Official record excerpt
Executive Order 14355 of September 30, 2025 Unlocking Cures for Pediatric Cancer With Artificial Intelligence By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered: Section 1 . Purpose and Policy. My Administration is committed to driving innovation to prevent and treat childhood diseases, including through the use of artificial intelligence (AI). Pediatric cancer remains the leading cause of disease-related death for children in the United States aged 1-19 years, and its incidence has increased by more than 40 percent since 1975. As outlined in my joint address to the Congress in March, reversing this trend is one of the top priorities for the Make America Healthy Again (MAHA) Commission established in Executive Order 14212 of February 13, 2025 (Establishing the President's Make America Healthy Again Commission). AI presents an opportunity to more quickly achieve this aim. In 2019, my Administration created the Childhood Cancer Data Initiative (CCDI), a Federal investment in childhood cancer research of $50 million in funding every year for 10 years to address the critical need to collect, generate, and analyze childhood cancer data. The CCDI is building a foundational data infrastructure, aggregating and generating new data, and using this data to make new discoveries. AI can be used to build upon this data initiative to produce meaningful solutions to pediatric, adolescent, and young adulthood cancer. This application of AI has the potential to transform the Nation's current care and research approach for pediatric cancer—as well as our healthcare and research infrastructure more broadly—through use of the rich and multimodal data, secured with appropriate individual privacy protections, to develop early and superior diagnostics, identify cures and optimize treatments, and advance medicine that will save lives. For too long, we have watched our children and their families battle cancer and its long-term chronic effects while healthcare systems often rely on outdated technologies and can be slow to adopt certain innovations. We must prioritize investment in AI-enabled science, build world-class scientific datasets, and empower researchers and clinicians with the tools needed to translate data and AI capabilities into improved care. Sec. 2 . Harnessing American AI Innovation. The MAHA Commission, in coordination with the Secretary of Health and Human Services (Secretary), the Assistant to the President for Science and Technology (APST), and the Special Advisor for AI and Crypto, and in alignment with the implementation of America's AI Action Plan, shall work to develop innovative ways to utilize advanced technologies such as AI to unlock improved diagnoses, treatments, cures, and prevention strategies for pediatric cancer. The initial focus shall be on identifying opportunities to accelerate the progress of AI-driven solutions at the CCDI, including by making data platforms and tools available as part of the CCDI Data Ecosystem and funding research projects at National Cancer Institute-Designated Cancer Centers that prioritize: (a) improving data infrastructure by consolidating data from multiple sources for AI-ready analysis and utilizing AI to better select participants for clinical trials; ( printed page 48154) (b) enhancing data analysis of complex biologic systems with AI tools to radically improve predictive modeling of patient response, disease progression, and treatment toxicity and to turn multi-omics data and imaging data into novel diagnostic, prognostic, and therapeutic biomarkers; and (c) improving clinical trial design, access, and outcomes for patients by incorporating multimodal data and using AI approaches to maximize utilization of the information from clinical trials and improve accessibility, recruitment, administration, conduct, and interpretation of clinical trial results. Sec. 3 . Increasing Investment and Engagement in Pediatric Cancer Research and Care Infrastructure. The MAHA Commission, in coordination with the Secretary, the Director of the Office of Management and Budget, the Director of the National Institutes of Health, and the APST, shall prioritize expanding pediatric cancer research and advancements in care by identifying and implementing strategies for: (a) increasing investment from existing Federal funds for the CCDI and other Federal Government initiatives that address pediatric cancer; and (b) encouraging the private sector to make use of the most advanced technologies to unlock cures for pediatric cancer, including those based on AI, to the maximum possible extent. Sec. 4 . Improving Data Sharing and Empowering Patients. The Secretary,
The excerpt is reproduced from the public federal record and may omit later sections, tables, signatures or attachments. Open the official source for the complete text.
Questions for accountability
- What legal authority does this economy action cite?
- Which agencies or officials were directed to act?
- What measurable implementation, cost, deadline or later court action followed?
How to use this page
This is a source-record entry, not a truth-rating by itself. It preserves the action, date and original government publication so it can be connected to later claims, implementation records, court decisions, costs and measurable outcomes. Editorial claim reviews on this site use separate finding labels and explain the evidence for those findings.